Barely Significant
← all excerpts

Ravulizumab and Efgartigimod in Myasthenia Gravis: A Real-World Study.

Neurol Neuroimmunol Neuroinflamm · 2025 · PMC11604103 · PMID 39602677

1
hedged sentence
closest p
boldest claim

The sentences

4 MG-ADL–based response rates in our real-world cohorts were considerably lower, and clinical efficacy assessed by the physician-reported QMG scale did not reach statistical significance in either treatment group after 4, 8, and 10 weeks.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.